Publications

5891 Results

KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424

Authors
PC Mack;M Redman;K Chansky;S Matsumoto;W Holland;P Lara;C Ambrosone;DR Gandara
Journal / Conference
Journal of Clinical Oncology 28:15s, 2010 (suppl; abstr 7013); ASCO annual meeting; poster
Year
2010
Research Committee(s)
Lung
Study Number(s)
S0424

A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19

Authors
GD Goss;I Lorimer;MS Tsao;CJ O'Callaghan;K Ding;GA Masters;D Gandara;JR Jett;MJ Edelman;FA Shepherd
Journal / Conference
Journal of Clinical Oncology 28:18s, 2010 (suppl; abstr LBA7005); ASCO annual meeting; poster
Year
2010
Research Committee(s)
Lung

A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC)

Authors
D Karp;J Lee;L Shaw Wright;DH Johnson;MR Johnston;GE Goodman;GH Clamon;GS Okawara;R Marks;J Ruckdeschel
Journal / Conference
Journal of Clinical Oncology 28:18s, 2010 (suppl; abstr CRA7004); ASCO Annual Meeting; oral
Year
2010
Research Committee(s)
Lung
Study Number(s)
E5597

Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study

Authors
HJ Bernstein;WT Barry;C Cirrincione;HK Chew;S Tolaney;D Lake;T Pluard;K Blackwell;E Winer;CA Hudis
Journal / Conference
Cancer Research 2010; 70(24 suppl 2 ): abstr PD05-01; SABCS annual meeting; poster discussion
Year
2010
Research Committee(s)
Breast

N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer

Authors
P Haluska;M Reinholz;AC Dueck;H Linden;W Lingle;AM Bernath;M Arbushites;H Youssoufian;HX Chen;EA Perez
Journal / Conference
Journal of Clinical Oncology 28:15s:(suppl; abstr TPS129); Trials in Progress poster presentation
Year
2010
Research Committee(s)
Breast

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082

Authors
LB Marks;C Cirrincione;TJ Fitzgerald;F Laurie;AS Glicksman;J Vredenburgh;LR Prosnitz;EJ Shpall;M Crump;PG Richardson;MW Schuster;J Ma;BL Peterson;L Norton;S Seagren;IC Henderson;DD Hurd;WP Peters
Journal / Conference
Int. J. Radiat. Oncol. Biol. Phys. 76(5):1305-1313
Year
2010
Research Committee(s)
Breast
PMID
PMID19747781
PMC
PMC3670136
Study Number(s)
SWOG-9114 (INT-0163) (CALGB-9082)

Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer

Authors
M Burnell;MN Levine;JW Chapman;V Bramwell;K Gelmon;B Walley;T Vandenberg;H Chalchal;K Albain;EA Perez;R Rugo;K Pritchard;P O'Brien;LE Shepherd
Journal / Conference
Journal of Clinical Oncology 28(1):77-82
Year
2010
Research Committee(s)
Breast
PMID
PMID19901117
PMC
PMC2799234

Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).

Authors
A Ajani;KA Winter;LL Gunderson;J Pedersen;A Benson;CR Thomas;RJ Mayer;MG Haddock;TA Rich;CG Willett
Journal / Conference
Cancer Sep 1;116(17):4007-4013
Year
2010
Research Committee(s)
Gastrointestinal
PMID
PMID20564111
PMC
PMC3831519
Study Number(s)
R9811

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node positive breast cancer: a phase 3 open-label, randomised controlled trial [PMID20004966; PMC3140679]

Authors
KS Albain;SJ Green;PM Ravdin;WB Farrar;GV Burton;SJ Ketchel;CD Cobau;EG Levine;JN Ingle;KI Pritchard;AS Lichter;DJ Schneider;MD Abeloff;IC Henderson;L Norton;D Lew;WE Barlow;RB Livingston;S Martino;CK Osborne
Journal / Conference
Lancet 374(9707):2055-2063
Year
2009
Research Committee(s)
Breast
Study Number(s)
SWOG-8814

Failure to achieve a complete response to induction BCG therapy is associated with increased risk of progression and death in patients with high risk non-muscle invasive bladder cancer [PMC2695968; PMID18367117]

Authors
SP Lerner;CM Tangen;H Sucharew;DP Wood;ED Crawford
Journal / Conference
Urologic Oncology 27(2):155-159
Year
2009
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8507